Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.40 |
| ▸ | JUN | P05412 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25253314 | 1.00 | NFE2L2 (0.45) | NFE2L2RELACYP1A1CYP1B1CYP1A2 | |
| SCHEMBL3511433 | 0.81 | TP53 (0.39) | NFE2L2RELAERN1KDM4ELMNA | |
| SCHEMBL3511431 | 0.81 | TP53 (0.39) | NFE2L2RELAERN1KDM4ELMNA | |
| SCHEMBL1824235 | 0.79 | CYP1A1 (0.68) | NFE2L2CYP1A1CYP1B1CYP1A2ABCG2 | |
| SCHEMBL1824237 | 0.79 | CYP1A1 (0.68) | NFE2L2CYP1A1CYP1B1CYP1A2ABCG2 | |
| SCHEMBL7483621 | 0.78 | NFE2L2 (0.54) | NFE2L2RELACYP1A1CYP1B1CYP1A2 | |
| SCHEMBL7484997 | 0.78 | CYP1A2 (0.44) | NFE2L2CYP1A1CYP1B1CYP1A2ERN1 | |
| SCHEMBL7485003 | 0.78 | CYP1A2 (0.44) | NFE2L2CYP1A1CYP1B1CYP1A2ERN1 | |
| SCHEMBL7483615 | 0.78 | NFE2L2 (0.54) | NFE2L2RELACYP1A1CYP1B1CYP1A2 | |
| SCHEMBL7491984 | 0.77 | NFE2L2 (0.41) | NFE2L2RELACYP1A1CYP1B1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | NFE2L2 177/4885RELA 338/4885CYP1A1 3563/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | NFE2L2 177/4885RELA 338/4885CYP1A1 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.